Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease
AEAVEX Life Sciences announce the results of up to 4 years of oral Blaclamesine about the experience of extending IIB / III open label, Alzheimer’s early morning
Report